Oligonucleotide (Antisense oligonucleotide) · Gene silencing: dystrophin (DMD) pre-mRNA, exon 45 (DMD) · developed by Sarepta Theraps
Casimersen is an antisense oligonucleotide that binds exon 45 of dystrophin pre-mRNA, causing the exon to be excluded during mRNA processing. This is intended to allow production of an internally truncated dystrophin protein. It is studied in Duchenne muscular dystrophy in patients with mutations amenable to exon 45 skipping.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03532542 | Phase 3 | Duchenne Muscular Dystrophy | Terminated | SRPT |
| NCT02500381 | Phase 3 | Duchenne Muscular Dystrophy | Completed | SRPT |
| NCT04179409 | Phase 2 | Duchenne Muscular Dystrophy | Completed | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular Dystrophy
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →